Legal status · United States
Is Orforglipron legal in the United States?
Yes. Orforglipron is an approved medicine in the United States, classified as "FDA-approved (Foundayo, chronic weight management), prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. Human evidence: Moderate.
Orforglipron in the United States at a glance
| Classification | FDA-approved (Foundayo, chronic weight management), prescription only |
|---|---|
| FDA approval status | FDA-approved April 1, 2026 as Foundayo for chronic weight management (boxed thyroid C-cell warning) |
| Evidence level | Moderate (research strength: Moderate) |
| Reviewed | Sep 2026 |
Classification and note come from the Orforglipron profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
FDA has approved Orforglipron for at least one labeled indication, so a pharmaceutical-grade product exists in the United States and is dispensed on prescription.
- 02
Approval is indication-specific. Uses outside the label are a clinical decision for a prescriber, not something the approval itself authorizes.
- 03
Unlicensed online vials, including those labeled "research use only", are not the approved product and are not covered by the approval.
What Orforglipron is
An investigational once-daily oral GLP-1 receptor agonist that is a small molecule rather than a peptide, studied for obesity and diabetes.
Orforglipron is an oral GLP-1 receptor agonist (FDA-approved April 2026 as Foundayo) notable for being a small-molecule pill rather than an injected peptide, which could make GLP-1 therapy easier to scale. Phase 2 and Phase 3 trials have reported meaningful weight loss and glucose lowering.
Mechanism: Activates the GLP-1 receptor as an orally available small molecule, reducing appetite and improving glucose-dependent insulin secretion.
Regulatory history: FDA-approved April 1, 2026 as Foundayo for chronic weight management (boxed thyroid C-cell warning)
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Orforglipron at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Orforglipron in other countries
Frequently asked questions
Is Orforglipron legal in the United States?
Yes. Orforglipron is an approved medicine in the United States, classified as "FDA-approved (Foundayo, chronic weight management), prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. Human evidence: Moderate.
Can I buy Orforglipron in the United States?
Only with a prescription. Orforglipron is classified as "FDA-approved (Foundayo, chronic weight management), prescription only" in the United States, so it is dispensed by pharmacies against a prescription for its approved indication. Buying it from unlicensed online sellers or as a "research chemical" is outside that system and carries no regulatory protection.
Is Orforglipron FDA approved?
Yes. FDA status: FDA-approved April 1, 2026 as Foundayo for chronic weight management (boxed thyroid C-cell warning). Current US classification: "FDA-approved (Foundayo, chronic weight management), prescription only". Evidence level: Moderate.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Orforglipron live on its compound profile.
Orforglipron profileThis page is general information about the regulatory status of Orforglipron in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.